Pemetrexed for the maintenance treatment of non-small-cell lung cancer

  • Technology appraisal guidance
  • TA190
  • Published: 
  • Last updated: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group:

  • Greenhalgh J et al. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer, October 2009

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers, or sponsors, were also invited to make written submissions. Professional or specialist and patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers, or sponsors, professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Manufacturer or sponsor:

  • Eli Lilly and Company

Professional or specialist and patient or carer groups:

  • British Thoracic Society (Lung Cancer and Mesothelioma Working party)

  • Cancer Research UK

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians, Medical Oncology Joint Special Committee

  • Royal College of Physicians' Intercollegiate Lung Cancer Group

  • Royal College of Radiologists

  • National Lung Cancer Forum for Nurses

  • Macmillan Cancer Support

  • Roy Castle Lung Cancer Foundation

Other consultees:

  • Department of Health

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Liverpool Reviews and Implementation Group, University of Liverpool

  • National Coordinating Centre for Health Technology Assessment

  • National Collaborating Centre for Cancer

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on Pemetrexed for the maintenance treatment of non-small-cell lung cancer by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Mike Lind, Consultant Medical Oncologist, nominated by the Royal College of Physicians – clinical specialist.

  • Dr Paul Bishop, Consultant Histopathologist, nominated by The Royal College of Pathologists – clinical specialist.

Representatives from the following manufacturer or sponsor attended Committee Meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Eli Lilly and Company